Literature DB >> 23994379

Measles antibody levels after vaccination with Edmonston-Zagreb and Schwarz measles vaccine at 9 months or at 9 and 18 months of age: a serological study within a randomised trial of different measles vaccines.

Cesario Martins1, May-Lill Garly, Carlitos Bale, Amabelia Rodrigues, Christine S Benn, Hilton Whittle, Peter Aaby.   

Abstract

UNLABELLED: Standard-titre Schwarz (SW) and Edmonston-Zagreb (EZ) measles vaccines (MV) are both used in the routine immunisation programme. Within a trial of different strains of MV, we examined antibody responses in both one-dose and two-dose schedules when the first dose was administered at 9 months. SETTING AND METHODS: The trial was conducted in an urban area in Guinea-Bissau where we have had a health and demographic surveillance system and studied strategies to prevent measles infection since 1978. In the present study, children were randomised to SW or EZ as the first MV and furthermore randomised to a second dose of the same MV or no vaccine at 18 months of age. We obtained blood samples from 996 children at baseline; post-vaccination blood samples were collected at 18 and 24 months of age to assess measles antibody levels after one or two doses of MV.
RESULTS: At age 18 months all had responded to the first dose and only 1% (8/699) of the children had non-protective antibody levels irrespective of vaccine type. SW was associated with significantly higher levels of measles antibodies (geometric mean titre (GMT)=2114 mIU/mL (95%CI 1153-2412)) than EZ (GMT=807 mIU/mL (722-908)) (p=0.001). Antibody concentration was significantly higher in girls than in boys after EZ but not after SW. Antibody levels were higher in the rainy than the dry season. There was no clear indication that a booster dose at 18 months increased the antibody level at 24 months of age.
CONCLUSIONS: Maternal antibody levels have declined significantly in recent years and 99% had protective levels of measles antibody following primary MV at 9 months of age. It is unlikely that measles prevention and child health will be improved by increasing the age of MV as currently recommended.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antibody response; Edmonston-Zagreb measles vaccine; Non-specific effects of vaccines; Schwarz measles vaccine; Two-dose measles vaccination

Mesh:

Substances:

Year:  2013        PMID: 23994379     DOI: 10.1016/j.vaccine.2013.08.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  The evolution of greater humoral immunity in females than males: implications for vaccine efficacy.

Authors:  Ashley L Fink; Sabra L Klein
Journal:  Curr Opin Physiol       Date:  2018-03-29

2.  Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial.

Authors:  K Zaman; Jessica A Fleming; John C Victor; Mohammad Yunus; Tajul Islam A Bari; Tasnim Azim; Mustafizur Rahman; Syed Mohammad Niaz Mowla; William J Bellini; Monica McNeal; Joseph P Icenogle; Ben Lopman; Umesh Parashar; Margaret M Cortese; A Duncan Steele; Kathleen M Neuzil
Journal:  J Infect Dis       Date:  2016-01-27       Impact factor: 5.226

Review 3.  Eradication of measles: remaining challenges.

Authors:  Heidemarie Holzmann; Hartmut Hengel; Matthias Tenbusch; H W Doerr
Journal:  Med Microbiol Immunol       Date:  2016-03-02       Impact factor: 3.402

4.  Serum Perfluoroalkyl Substances, Vaccine Responses, and Morbidity in a Cohort of Guinea-Bissau Children.

Authors:  Clara Amalie Gade Timmermann; Kristoffer Jarlov Jensen; Flemming Nielsen; Esben Budtz-Jørgensen; Fiona van der Klis; Christine Stabell Benn; Philippe Grandjean; Ane Bærent Fisker
Journal:  Environ Health Perspect       Date:  2020-08-10       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.